Respreeza

alpha-1 proteinase inhibitor (human) · CSL Behring

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Respreeza, covering 2025-03-27 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) [Phase 4]

See pricing